Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Nomilin in Preparation of Drugs for Improving Liver Damage Caused by Cholestasis and Metabolic Diseases

A technology for metabolic diseases and cholestasis, which can be used in drug combinations, pharmaceutical formulations, organic active ingredients, etc., and can solve the problems of complex pathogenesis of metabolic diseases.

Active Publication Date: 2021-07-13
SHANGHAI UNIV OF T C M
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the complex pathogenesis of metabolic diseases, there are currently no safe and effective drugs to treat them.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Nomilin in Preparation of Drugs for Improving Liver Damage Caused by Cholestasis and Metabolic Diseases
  • Application of Nomilin in Preparation of Drugs for Improving Liver Damage Caused by Cholestasis and Metabolic Diseases
  • Application of Nomilin in Preparation of Drugs for Improving Liver Damage Caused by Cholestasis and Metabolic Diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0126] Animal model

[0127] High-fat feed-induced obesity mice (DIO) experiments.

[0128] Mouse modeling and grouping

[0129] 7 weeks old, C57BL / 6SPF female mice, after 1 week of the animal room, leaving the CHOW group to give normal feed, and the rest of the high-fat feed induced obesity and induced for 3 months. After picking up 30-40 g of obesity mice that have been successfully molded, 8 of the groups, 8 SPSS21.0 software analysis, and there is no difference in weight between each group. Divided into: normal control group, high-fat control group, high fat + ovalcholic acid group, high fat + Nimin group.

[0130] Dosage dose and method

[0131] Obberry: 15mg / kg bodyweight / day (0.2 / 1000 high fat feed)

[0132] Nomin: 75mg / kg bodyweight / day (1 / 1000 high fat feed)

[0133] According to the above dose, first mash the high fat feed, then add the drug powder, mix evenly, make a cylindrical feed. Feeding the mice and administered for 7 weeks. During the period, the food...

Embodiment 2

[0140] Ob / OB leptin lack of obesity mouse experiment

[0141] Mouse modeling and grouping

[0142] Ob / OB mice, 12 weeks old, female, SPF level, with a weight of about 80g. All give ordinary feed. According to the weight random group, 6 of each group, SPSS21.0 software analysis, and there is no difference between the groups. Divided into: Normal group, OB / OB model group, OB / OB + Nimin (75mg / kg)

[0143] Dosage dose and method

[0144] Improving administration, once a day, continuously fed a month, drug Nomilin: 75 mg / kg, dissolved in 0.5% CMCNA, in the ultrasonic ultrasound to form a suspension.

[0145] Impact of Nimlin on the liver of OB / OB mice

[0146] By analyzing the pathological analysis of OB / OB mouse liver HE: Compared with normal mice, the hypoth of liver in the model group is very serious, and there is a void deformation (OB / OB mice HE staining and liver Tc, Tg content) Such as Figure 4 Disted, where Pic 4-1 The pathological sections of the liver hepati...

Embodiment 3

[0148] MCD feed-induced fatty hepatitis (NASH) mouse experiment

[0149] Mouse modeling and grouping

[0150] 7 weeks old, C57BL / 6SPF female mice, raised from 20-25g of animal houses in Shanghai Traditional Chinese Medicine to remove the normal group to give MCS feed, and all of the remaining MCD feeds, 3 weeks of modeling, according to the weight random group, Each group, SPSS21.0 software analysis, and there is no difference in weight between each group. Divided into: MCS control group, MCD model group, Obecholic acid group, Nimin (75mg / kg).

[0151] Dosage dose and method

[0152] Irrush, once a day, 4 weeks. Nomin: 75 mg / kg, dissolved in 0.5% CMCNA, and the ultrasonic ultrasound is used as a suspension.

[0153] Nomin improves the liver fat degeneration of MCD feed induced mice

[0154] In order to further study the therapeutic effect of Namilin's alcoholic fatty liver, we used MCD feed-induced fatty hepatitis model NASH, induced by C57BL / 6 after 3 weeks of MCD, admini...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the application of nomilin in the preparation of medicines for improving liver damage caused by cholestasis and metabolic diseases, and belongs to the technical field of medicine preparation. The present invention provides the application of nomilin in the preparation of medicines for improving liver damage caused by cholestasis and metabolic diseases. Nomilin can significantly improve liver damage by improving bile acid metabolism, anti-inflammatory, anti-oxidative stress, and reducing lipid synthesis.

Description

Technical field [0001] The present invention relates to the field of medication preparation, and in particular, in the preparation of drugs in the preparation of drug injuries such as bile sludge and metabolic diseases. Background technique [0002] With the development of socio-economic, people's living standards, changes in diet, have become increasing, such as obesity, diabetes, insulin resistance, hypertension, hyperlipidemia. The liver is an important organ that regulates metabolism such as sugar, fat, protein, and bile acid, and is also a central government that maintains the balance in the body. If the liver damage, the liver cell viability is lowered, the detoxification function is weakened, and the sensitivity of the injury factor such as oxidative stress is increased, and the inflammation, fibrosis, and the like are further caused. The liver injury caused by metabolic diseases is mainly manifested as liver damage caused by non-alcoholic fatty liver (NAFLD) and bile acid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/585A61P1/16
CPCA61K31/585A61P1/16
Inventor 黄诚范圣洁骆玲玲曹禹李鸿丽李俊晓方金安
Owner SHANGHAI UNIV OF T C M
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com